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Reply to Moodley and to Ravaglia et al.
From the Authors:
We thank Moodley for surfacing potential concerns about the
radiological and histopathological features of idiopathic pulmonary
fibrosis (IPF) that we refined in the new clinical practice guideline
focused on the diagnosis of IPF (1).
The probable UIP pattern is based on the depiction of the
second major radiological feature that enables the radiologist to
assess lung fibrosis, namely traction bronchiolectasis. In this
category, the high-resolution computed tomography (HRCT)
features of reticulation, ground glass opacification (GGO), and
distortion are minor changes, variably associated with peripheral
traction bronchiolectasis.
We introduced the subcategory of early usual interstitial
pneumonia (UIP) to alert the individual clinical scenario of IPF
relatively early in the disease course. This interest is triggered by the
possibility of detection of subclinical interstitial lung disease in
smokers that can evolve toward obvious fibrosis on CT follow-up
(2–6). Although uncertainty still remains regarding the long-term
prognostic implications of subclinical interstitial lung disease (3), it
may be relevant to investigate these situations in select populations,
with the ultimate goal of recognizing and treating IPF earlier.
The degree of lung attenuation is influenced by numerous
variables on HRCT examinations, varying from the degree of
inspiration to the kernels of reconstruction. Therefore, there is no
recommendation for defining GGO with quantitative variables.
Although they can be proposed in clinical research programs, they
are not applicable to routine clinical practice.
Contrary to Moodley’s statement, the presence of traction
bronchiectasis was not clearly stated in the previous “possible UIP”
category. The only difference was the absence of honeycombing.
Removing GGO from the probable category would not make
great differences in the categorization of patients. The indeterminate
pattern (“truly indeterminate”) corresponds to HRCT features that do
not correspond to an HRCT pattern of UIP, nor do they suggest any
specific etiology for lung fibrosis. Among the HRCT features reported
as indeterminate for UIP on CT sections, one can describe GGO of
high attenuation; this HRCT feature has no further diagnostic value.
Moodley also raises an important issue, acknowledging that in
circumstance of uncertainty regarding the histopathologic features
conveyed by terms like “probable” or “indeterminate,” the
uncertainty often centers on the difficulty of consistently separating
the fibrotic variant of nonspecific interstitial pneumonia (NSIP)
from UIP/IPF. The histologic features that define fibrotic NSIP are
nonspecific, as the term implies, precisely because this same
histology can occur focally (“NSIP-like changes”) in other
conditions, including UIP/IPF. For that reason, deciding that a
biopsy diagnosis of a fibrotic NSIP pattern is representative of a
patient’s underlying condition is necessarily a matter of exclusion.
In that sense, patients with biopsy diagnoses of fibrotic NSIP may
indeed have UIP/IPF, depending on other information.
Because HRCT is imperfect in separating patients with fibrotic
NSIP from patients with UIP/IPF who lack diagnostic radiological
findings, it remains true that some patients considered to have
fibrotic NSIP at diagnosis will ultimately prove to have UIP/IPF
over time. This reflects the imperfect state of the art and the
vulnerabilities that persist even in the context of multidisciplinary
discussion. We agree that different groups of pulmonologists,
radiologists, and pathologists may resolve these levels of uncertainty
differently, meaning that patients assigned to a category of fibrotic
NSIP in one institution may legitimately be assigned to other
categories, including UIP/IPF, by others. This remains a key area
for further investigation, with the hope of greater diagnostic
reproducibility and precision.
Finally, Moodley raises the consideration of using combinations
of antiinflammatory agents besides antifibrotic treatment strategy
for patients with a new diagnosis of IPF, because subjects with
subtle inflammation (suggested by allowance of some GGO in the
appropriate clinical setting and meeting other criteria of the UIP
pattern in the new guideline for the diagnosis of IPF)will be diagnosed
with IPF from now on. Because the guideline focused on the diagnosis
of IPF, the discussion regarding the therapeutic role of antifibrotics
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and/or other antiinflammatory agents is indeed beyond the
scope of the 2018 guideline and is a subject of much-needed
future studies.
We also thank Ravaglia and colleagues for their interest in
the new clinical practice guidelines (CPG) that we developed on
diagnosis of IPF (1). In the guidelines, we pointed out that
transbronchial lung cryobiopsy (TLCB) and surgical lung biopsy
(SLB) have procedural mortalities of 0.2% and 1.7%, respectively.
As summarized in the new CPG, there were (and are to date,
to our knowledge) no randomized controlled trials that offer a
comparison of patient outcomes for TLCB compared with SLB.
Conclusions and recommendations were made based on pooling
studies of selected cohorts. The authors express concern that the
approach for which they advocate—TLCB followed by SLB when the
former is inadequate or nondiagnostic—will be construed as having
a procedural mortality of 1.9%. The authors argue that the diagnostic
yield of TLCB indicates that only 20% of patients require both
procedures, with an anticipated average procedural mortality of
1.9%; most patients require only TLCB, with an average procedural
mortality of only 0.2%. We agree; however, we advocate that this
information be conveyed by presenting both ends of the spectrum,
because it cannot be known in advance whether one or two
procedures will be needed.
The reported SLB procedural mortality of 1.7% may not reflect
the mortality risks in patients who are more severely ill; it is probably
higher among more severely ill patients. We were unable to stratify
the procedural mortality for SLB according to severity of illness;
however, procedural mortality ranged from 0% to 4.4%, and the
variation may have reflected differences in severity of illness,
operator experience, etc. The potential for higher risk of mortality
and complications associated with SLB in patients who are more sick
with more severe impairment in lung function tests, oxygenation,
and/or associated pulmonary hypertension is indeed a concern
and is described in the guideline (“Surgical lung biopsy is not
indicated in patients at high risk for intra-, peri-, or postoperative
complications [e.g., severe hypoxemia at rest and/or severe
pulmonary hypertension with a diffusion capacity less than
25% after correction for hematocrit]”). The risk of the
complications/mortality associated with TLCB in similar patients is
unknown. The data reported to date with TLCB are for patients
who are ambulatory, and TLCB is performed as an elective
outpatient procedure in most, if not all, patients. Further studies
comparing TLCB to SLB in comparable cohorts controlled for
disease severity are needed to support the argument made by
Ravaglia and colleagues. In addition, the standard of care for SLB
that has evolved over the last several years is to obtain wedge
biopsies from two to three different lobes to increase the diagnostic
yield, and this is based on the documented histopathologic
variability in SLB from different lobes (7). The majority of reports
to date for TLCB indicate that tissue is obtained from one lobe;
complication rates and diagnostic yield for TLCB from different
lobes are not yet known.
We trust that readers will understand that our reported
procedural mortality reflects the average patient and will recognize
that procedural mortality associated with TLCB and/or SLB may
be higher in more severely ill patients and lower in less severely
ill patients. As proposed in the new CPG for the diagnosis of
IPF, the procedure and technique for TLCB suffers from lack of
standardization—thus, the importance of restricting TLCB in its
current state to experienced experts (1). Well-designed studies with
sequential lung biopsies (TLCB and SLB) from the same lobe are
needed to settle the question of TLCB versus SLB as most
appropriate diagnostic procedures to obtain the lung biopsy for
histopathology diagnosis. It is hoped that ongoing and future
studies worldwide will provide the much-needed results and settle
the issue. n
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Erratum: Implications of Procalcitonin Testing in
Critically Ill Patients with Sepsis
There was an error in the order of the authors for the January 15,
2019, Recommended Reading feature: Dr. Jessica L. Nelson
should have been listed as the first author. The corrected author
line should read:
Jessica L. Nelson, Christopher K. Hansen, Thomas M. Scupp,
and Jason C. Brainard. n
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